ASCO 2012 Report – Combination targeted therapy shows efficacy and fewer toxicities in advanced melanoma treatment
by Bruce Sylvester – Results from an expanded Phase IB trial presented at ASCO suggest that combination therapy with two investigational and targeted drugs, BRAF inhibitor dabrafenib and… read more.